Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 320-67-2] 5-Azacytidine

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-10586
Brand:	MCE
CAS:	320-67-2

Overview

MDL	MFCD00006539
Molecular Weight	244.20
Molecular Formula	C8H12N4O5
SMILES	O[C@H]1[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO

For research use only. We do not sell to patients.

39 Publications Citing Use of MCE

[1]Mol Cell. 2022 Sep 29;S1097-2765(22)00896-6.
[2]Nat Commun. 2022 May 13;13(1):2672.
[3]Cancer Res. 2020 Feb 1;80(3):406-417.
[4]Leukemia. 2021 Jun 1.
[5]Theranostics. 2021 Jan 1;11(5):2318-2333.
[6]Sci Data. 2022 Oct 8;9(1):610.
[7]Oncogene. 2021 Apr;40(15):2711-2724.
[8]BMC Biol. 2021 Sep 7;19(1):192.
[9]Mol Oncol. 2018 Feb;12(2):180-195.
[10]Antioxid Redox Signal. 2021 Jul;35(1):1-20.
[11]Cell Death Dis. 2018 Apr 27;9(5):497.
[12]Cell Death Dis. 2018 Jan 26;9(2):129.
[13]PLoS Pathog. 2020 Mar 24;16(3):e1008429.
[14]Cancers (Basel). 2023, 15(2), 417.
[15]Front Cell Dev Biol. 2021 Apr 30;9:667435.
[16]Front Cell Dev Biol. 2021 Apr 30.
[17]Int J Biol Macromol. 2022.
[18]Acta Pharmacol Sin. 2021 Apr 13.
[19]Ecotoxicol Environ Saf. 2020 Dec 1;205:111089.
[20]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
[21]Cell Commun Signal. 2019 Aug 14;17(1):94.
[22]Dig Liver Dis. 2021 Sep 26;S1590-8658(21)00772-6.
[23]Int Immunopharmacol. 2022 Aug 6;111:109113.
[24]Invest New Drugs. 2022 May 16.
[25]Ann Transl Med. 2020 Mar;8(6):373.
[26]Ann Transl Med. 2020 Mar;8(6):329.
[27]Nutr Metab. 2020 May 27;17:41.
[28]PPAR Res. 2021 Apr 19.
[29]PLoS One. 2019 Sep 6;14(9):e0222298.
[30]Dis Markers. 11 Jul 2022.
[31]SLAS Discov. 2018 Aug;23(7):687-696.
[32]bioRxiv. 2023 Jan 9.
[33]Research Square Print. September 9th, 2022.
[34]Pharmaceuticals. 2021, 14(8), 749.
[35]Research Square Preprint. 2021 Jun.
[36]Research Square Preprint. 2021 Feb.
[37]University of Colorado. Department of Molecular, Cellular and Developmental Biology. 2020 Dec.
[38]Patent. US20180263995A1.
[39]Harvard Medical School LINCS LIBRARY

Summary

5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes ^[1] ^[2] . 5-Azacytidine induces cell autophagy ^[4] .

IC50 & Target

DNMT1

Nucleoside Antimetabolite/Analog

Autophagy

In Vitro

Unmethylated CpG islands associated with a variety of genes become partially or fully methylated in tumors and can be reactivated by 5-Azacytidine ^[1] . 5-Azacytidine acts as weak inducers of erythroid differentiation of Friend erythroleukemia cells in the same concentration range where they affect DNA methyltransferase activity ^[2] . 5-Azacytidine inhibits L1210 cells with ID ₅₀ and ID ₉₀ values of 0.019 and circa 0.15 μg/mL, respectively ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TdR- ³ H incorporation is significantly inhibited when the animals are exposed to 5-Azacitidine (100 mg/kg, i.p.) for 2 hr or longer ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04603001	Eli Lilly and Company\|Loxo Oncology, Inc.	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|Myeloproliferative Neoplasms (MPNs)	December 1, 2020	Phase 1
NCT02129101	Mayo Clinic\|National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Essential Thrombocythemia\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm\|Polycythemia Vera\|Previously Treated Myelodysplastic Syndrome\|Primary Myelofibrosis\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	May 2014	Phase 1
NCT05149378	The First Affiliated Hospital of Soochow University\|Jining Medical University\|The Second People´s Hospital of Huai´an\|First Affiliated Hospital Bengbu Medical College\|Northern Jiangsu Province People´s Hospital\|Affiliated Hospital of Nantong University\|Suzhou Hospital of Traditional Chinese Medicine	Acute T-Lymphocytic Leukemia	November 1, 2021	Phase 2
NCT00503984	University of Miami	Prostate Cancer\|Pain	May 2007	Phase 1\|Phase 2
NCT05603884	The First Affiliated Hospital of Xiamen University\|Chipscreen Biosciences, Ltd.\|CSPC Pharmaceutical Group Limited\|Fujian Provincial Hospital\|Fujian Cancer Hospital\|Zhangzhou manicipal hospital of Fujian Province\|Jieyang People´s Hospital\|Huizhou Municipal Central Hospital	Leukemia, Myeloid, Acute\|AML Stage, Adult	December 1, 2022	Phase 2
NCT02450877	Celgene	Leukemia, Myeloid, Acute	August 12, 2015	Phase 2
NCT04128501	M.D. Anderson Cancer Center	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|Mixed Phenotype Acute Leukemia\|T Acute Lymphoblastic Leukemia\|Therapy-Related Acute Myeloid Leukemia	May 5, 2020	Phase 2
NCT04266795	Takeda	Acute Myeloid Leukemia (AML)	October 13, 2020	Phase 2
NCT00446303	Groupe Francophone des Myelodysplasies\|Celgene Corporation	Leukemia, Myelocytic, Acute\|Myelodysplastic Syndromes	July 2006	Phase 2
NCT00496444	M.D. Anderson Cancer Center\|Celgene Corporation	Advanced Cancers	May 2005	Phase 1
NCT01748240	Groupe Francophone des Myelodysplasies\|Merck Sharp & Dohme LLC	Myelodysplastic Syndrome	March 2013	Phase 2
NCT01016600	Washington University School of Medicine\|Celgene Corporation	Leukemia, Myeloid, Acute	April 2010	Phase 1\|Phase 2
NCT01935947	National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	May 2013	Phase 2
NCT02265510	Incyte Corporation	Solid Tumors\|Advanced Malignancies\|Metastatic Cancer	September 10, 2014	Phase 1\|Phase 2
NCT00321711	Amgen	MDS\|Myelodysplastic Syndromes\|Thrombocytopenia	October 1, 2006	Phase 2
NCT01787487	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Myelofibrosis Transformation in Essential Thrombocythemia\|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase\|Primary Myelofibrosis	March 13, 2013	Phase 2
NCT05126004	The First Affiliated Hospital of Soochow University	Thrombocytopenia, Isolated\|Stem Cell Transplant Complications	December 1, 2021	Phase 2
NCT03862157	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Chronic Eosinophilic Leukemia, Not Otherwise Specified\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Essential Thrombocythemia\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Myeloid Neoplasm\|Myeloproliferative Neoplasm\|Myeloproliferative Neoplasm, Unclassifiable\|Overt Primary Myelofibrosis\|Polycythemia Vera\|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase\|Prefibrotic+Early Primary Myelofibrosis	February 27, 2019	Phase 1\|Phase 2
NCT00901069	Shams Shakil\|Celgene\|University of Kentucky	Lymphoma\|Hodgkin Disease\|Lymphoma, Non-Hodgkin	May 2009	Phase 1
NCT03765541	University Hospital, Toulouse	Relapsed or Refractory Acute Myeloid Leukemia	January 13, 2020	Phase 3
NCT05282719	The First Affiliated Hospital of Soochow University	Myelodysplastic+Myeloproliferative Neoplasms\|Adult	April 2022	Phase 2
NCT02458235	University of California, San Francisco\|Hellman Foundation	Acute Myelogenous Leukemia\|Acute Lymphoid Leukemia\|Juvenile Myelomonocytic Leukemia\|Myelodysplastic Syndrome	June 2, 2015	Phase 2
NCT01522976	National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Chronic Myelomonocytic Leukemia-1\|Chronic Myelomonocytic Leukemia-2\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Excess Blasts-1\|Myelodysplastic Syndrome With Excess Blasts-2	March 1, 2012	Phase 2
NCT04742101	Institut de Recherches Internationales Servier\|ADIR, a Servier Group company\|Servier	Acute Myeloid Leukemia	March 10, 2021	Phase 1\|Phase 2
NCT00351975	National Cancer Institute (NCI)	Accelerated Phase of Disease\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blastic Phase\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia\|Previously Treated Myelodysplastic Syndrome\|Primary Myelofibrosis\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Disease\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome	June 2006	Phase 1
NCT04578600	Joseph Tuscano\|National Cancer Institute (NCI)\|Celgene\|University of California, Davis	Indolent B-Cell Non-Hodgkin Lymphoma\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Hairy Cell Leukemia\|Recurrent Lymphoplasmacytic Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Mucosa-Associated Lymphoid Tissue Lymphoma\|Refractory Follicular Lymphoma\|Refractory Hairy Cell Leukemia\|Refractory Lymphoplasmacytic Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Small Lymphocytic Lymphoma	October 23, 2020	Phase 1
NCT04937166	Kahr Medical	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia	January 13, 2022	Phase 1
NCT04275518	Ascentage Pharma Group Inc.\|Suzhou Yasheng Pharmaceutical Co., Ltd.	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndromes (MDS)	July 6, 2020	Phase 1
NCT03466294	University of Colorado, Denver	Acute Myeloid Leukemia	May 15, 2018	Phase 2
NCT02610777	Millennium Pharmaceuticals, Inc.\|Takeda	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute	April 14, 2016	Phase 2
NCT04891068	University of Illinois at Chicago	Breast Cancer Female\|Breast Cancer Invasive	January 10, 2022	Phase 2
NCT03268954	Takeda\|Takeda Development Center Americas, Inc.	Myelodysplastic Syndrome\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute	November 28, 2017	Phase 3
NCT04172844	Medical College of Wisconsin	Acute Myelogenous Leukemia	January 13, 2020	Phase 1
NCT02752035	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation	August 1, 2016	Phase 3
NCT05471700	Zhujiang Hospital	Leukemia, Myeloid, Acute	August 1, 2022	Phase 1\|Phase 2
NCT03113643	Dana-Farber Cancer Institute\|Stemline Therapeutics, Inc.	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Blastic Plasmacytoid Dendritic Cell Neoplasm	June 26, 2017	Phase 1
NCT04480125	Ruijin Hospital	Peripheral T-cell Lymphoma	June 20, 2020	Phase 2
NCT04905407	Syros Pharmaceuticals	Acute Myeloid Leukemia	August 26, 2021	Phase 2
NCT02343939	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2015	Phase 1\|Phase 2
NCT02587598	Incyte Corporation	Solid Tumors	December 29, 2015	Phase 1\|Phase 2
NCT03483948	Hutchison Medipharma Limited\|Hutchmed	Acute Myeloid Leukemia	October 9, 2018	Phase 1
NCT04778397	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2021	Phase 3
NCT02675452	Amgen	Relapsed or Refractory Multiple Myeloma\|Relapsed or Refractory Acute Myeloid Leukemia	June 13, 2016	Phase 1
NCT00387647	H. Lee Moffitt Cancer Center and Research Institute\|Celgene Corporation	Leukemia	August 2006	Phase 2
NCT05365035	M.D. Anderson Cancer Center	Myelodysplastic Syndromes\|Myeloproliferative Chronic Myelomonocytic Leukemia	September 23, 2022	Phase 2
NCT03151304	Helsinn Healthcare SA	Myelodysplastic Syndromes	June 1, 2017	Phase 2
NCT01121757	Duke University\|Celgene	Follicular Lymphoma\|Marginal Zone Lymphoma	April 2010	Phase 2
NCT04140487	M.D. Anderson Cancer Center	Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic+Myeloproliferative Neoplasm\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic+Myeloproliferative Neoplasm	December 17, 2019	Phase 1\|Phase 2
NCT02203773	AbbVie\|Genentech, Inc.	Acute Myelogenous Leukemia\|Myelogenous Leukemia\|Treatment Naive AML	October 6, 2014	Phase 1
NCT02929498	GlaxoSmithKline\|Parexel	Myelodysplastic Syndrome\|Myelodysplastic Syndromes	July 31, 2017	Phase 1\|Phase 2
NCT04712942	University of Leipzig\|Millennium Pharmaceuticals, Inc.	Acute Myeloid Leukemia in Remission\|Myelodysplastic Syndromes\|Minimal Residual Disease	January 1, 2021	Phase 2
NCT03383575	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Celgene	Acute Myeloid Leukemia\|Blasts 20-30 Percent of Bone Marrow Nucleated Cells\|Chronic Myelomonocytic Leukemia\|IDH2 Gene Mutation\|Myelodysplastic Syndrome With Excess Blasts\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory High Risk Myelodysplastic Syndrome	January 17, 2018	Phase 2
NCT01290302	American Regent, Inc.	Myelodysplastic Syndrome\|Myelofibrosis\|Chronic Myeloid Leukemia\|Chronic Lymphocytic Leukemia	October 2010	Phase 1
NCT02260440	Anuradha Krishnamurthy\|Merck Sharp & Dohme LLC\|University of Pittsburgh	Metastatic Colorectal Cancer	January 2015	Phase 2
NCT01957644	Boehringer Ingelheim	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	November 6, 2013	Phase 1
NCT00234000	Jonsson Comprehensive Cancer Center\|CTI BioPharma\|Celgene Corporation	Leukemia\|Myelodysplastic Syndromes	February 2007	Phase 1
NCT02038816	Sunnybrook Health Sciences Centre\|Novartis	Myelodysplastic Syndromes	March 2014	Phase 2
NCT03745716	Aprea Therapeutics	MDS	January 11, 2019	Phase 3
NCT02009436	Albert Einstein College of Medicine\|National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IV Non-Small Cell Lung Cancer	February 9, 2015	Phase 1
NCT00384956	Washington University School of Medicine	Myelodysplastic Syndromes	August 2006	Phase 2
NCT03397173	Case Comprehensive Cancer Center	Myelodysplastic Syndromes\|Myeloproliferative Neoplasm\|Acute Myeloid Leukemia	March 16, 2018	Phase 2
NCT04161885	AbbVie	Acute Myeloid Leukemia (AML)\|Cancer	February 26, 2020	Phase 3
NCT00948064	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|Celgene Corporation	Leukemia	September 8, 2009	Phase 2
NCT01983969	M.D. Anderson Cancer Center	Advanced Cancers\|Lymphoma	November 7, 2013	Phase 1\|Phase 2
NCT00350818	M.D. Anderson Cancer Center\|Celgene Corporation	Myelodysplastic Syndrome\|Leukemia	October 2005	Phase 1
NCT00071799	Celgene	Myelodysplastic Syndromes	November 1, 2003	Phase 3
NCT02599649	M.D. Anderson Cancer Center\|Bristol-Myers Squibb	Leukemia	March 21, 2016	Phase 2
NCT01743859	University of Colorado, Denver\|Celgene	Acute Myeloid Leukemia	December 6, 2012	Phase 2
NCT01908387	Celgene Corporation\|Celgene	Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|Acute Myeloid Leukemia\|Multiple Myeloma\|Non-Hodgkin Lymphoma\|Hodgkin Lymphoma	July 2013	Phase 1
NCT04241549	Janssen Pharmaceutical K.K.\|argenx	Leukemia, Myeloid, Acute	March 25, 2020	Phase 1
NCT04264806	Janssen Research & Development, LLC\|argenx	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	May 6, 2021	Phase 2
NCT03238248	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Myelodysplastic Syndromes\|Myeloproliferative Neoplasm	August 7, 2017	Phase 2
NCT01074047	Celgene	Acute Myeloid Leukemia	June 1, 2010	Phase 3
NCT01202877	M.D. Anderson Cancer Center\|Novartis Pharmaceuticals\|Celgene Corporation	Leukemia	March 2011	Phase 1\|Phase 2
NCT01556477	Nordic MDS Group	Myelodysplastic Syndrome\|Acute Myelogenous Leukemia	March 2012	Phase 2
NCT04150887	Janssen Research & Development, LLC\|argenx	Leukemia, Myeloid, Acute	December 23, 2019	Phase 1
NCT01011283	Eisai Inc.	Myelodysplastic Syndromes	November 2009	Phase 4
NCT04160052	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Recurrent Myelodysplastic Syndrome\|Refractory Myelodysplastic Syndrome\|Therapy-Related Myelodysplastic Syndrome	October 1, 2019	Phase 1\|Phase 2
NCT04511975	Innovent Biologics (Suzhou) Co. Ltd.	MDS	August 24, 2020	Phase 1
NCT01105377	National Cancer Institute (NCI)	Recurrent Colon Cancer\|Recurrent Rectal Cancer\|Stage IV Colon Cancer\|Stage IV Rectal Cancer	April 2010	Phase 2
NCT02712905	Incyte Corporation	Solid Tumors and Hematologic Malignancy	May 5, 2016	Phase 1\|Phase 2
NCT00382590	M.D. Anderson Cancer Center	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome\|Leukemia	August 2005	Phase 2
NCT04435691	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	July 28, 2020	Phase 1\|Phase 2
NCT03745352	National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	May 20, 2019	Phase 2
NCT01794169	Karolinska University Hospital\|Celgene Corporation	Acute Myeloid Leukemia	March 2013	Phase 2
NCT04803201	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Angioimmunoblastic T-cell Lymphoma\|Enteropathy-Associated T-Cell Lymphoma\|Follicular T-Cell Lymphoma\|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma\|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma\|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype\|Peripheral T-Cell Lymphoma, Not Otherwise Specified	July 30, 2021	Phase 2
NCT01180322	University of Ulm	Acute Myeloid Leukemia (AML)	November 2010	Phase 2
NCT02816021	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|Celgene	Melanoma and Other Malignant Neoplasms of Skin\|Metastatic Melanoma	February 14, 2017	Phase 2
NCT00381693	Mayo Clinic\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Secondary Myelofibrosis	August 2006	Phase 2
NCT00543582	Mirati Therapeutics Inc.	Hodgkin Lymphoma\|Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)	October 2007	Phase 2
NCT01812252	Fred Hutchinson Cancer Center	Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Secondary Myelodysplastic Syndrome	April 2, 2013	Phase 2
NCT02096042	M.D. Anderson Cancer Center\|Seagen Inc.	Leukemia	April 2014	Phase 1\|Phase 2
NCT03699384	Memorial Sloan Kettering Cancer Center\|Pfizer	Acute Myeloid Leukemia (AML)\|Minimal Residual Disease	October 3, 2018	Phase 1\|Phase 2
NCT03978364	Shandong Provincial Hospital	Myelodysplastic Syndromes,Acute Myeloid Leukemia	June 1, 2019	Phase 3
NCT00666497	Mirati Therapeutics Inc.	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	June 2008	Phase 2
NCT02269280	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Leukemia	October 13, 2014	Phase 2
NCT00528983	Celgene	Myelodysplastic Syndromes (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|Acute Myelogenous Leukemia (AML)	September 11, 2007	Phase 1
NCT02159040	Novartis Pharmaceuticals\|Novartis	High Risk MDS	September 11, 2014	Phase 2
NCT04913922	Ludwig-Maximilians - University of Munich	Acute Myeloid Leukemia	May 5, 2021	Phase 2
NCT02397720	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	April 7, 2015	Phase 2
NCT05367401	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Acute Myeloid Leukemia	December 20, 2024	Phase 1\|Phase 2
NCT01065129	Washington University School of Medicine	Myelodysplastic Syndromes	September 2, 2010	Phase 1
NCT05008666	Sun Yat-sen University	Safety and Efficacy	December 1, 2021	Phase 2
NCT04964505	Brian Jonas\|GlycoMimetics Incorporated\|National Cancer Institute (NCI)\|University of California, Davis	Acute Myeloid Leukemia	July 2, 2021	Phase 1
NCT01617226	University of Birmingham\|Leukemia Research Fund\|Celgene\|Merck Sharp & Dohme LLC	Leukemia, Myeloid, Acute	September 2012	Phase 2
NCT05559008	Ruijin Hospital	Peripheral T Cell Lymphoma	September 30, 2022	Phase 1\|Phase 2
NCT03164057	St. Jude Children´s Research Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	June 15, 2017	Phase 2
NCT00901537	Loma Linda University	Non-small Cell Lung Cancer\|Squamous Cell Carcinoma of the Head and Neck	February 2009	Phase 1
NCT00101179	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Leukemia\|Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome	November 3, 2004	Phase 1
NCT01038635	M.D. Anderson Cancer Center\|Celgene	Leukemia	December 2009	Phase 1\|Phase 2
NCT01913951	Washington University School of Medicine\|Sunesis Pharmaceuticals	Myelodysplastic Syndromes	November 22, 2013	Phase 1
NCT03486353	Fujifilm Pharmaceuticals U.S.A., Inc.	Myelodysplastic Syndrome (MDS)	October 2019	Phase 2
NCT03194932	St. Jude Children´s Research Hospital\|Gateway for Cancer Research	Acute Myeloid Leukemia	July 11, 2017	Phase 1
NCT00887068	M.D. Anderson Cancer Center\|Celgene	Leukemia\|AML\|MDS	April 21, 2009	Phase 3
NCT01200004	M.D. Anderson Cancer Center\|Yukiguni Maitake Company Ltd.	Advanced Cancers	April 2012	Phase 1
NCT00529022	M.D. Anderson Cancer Center\|Celgene Corporation	Solid Tumors	August 2007	Phase 1
NCT01168219	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With Minimal Differentiation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Alkylating Agent-Related Acute Myeloid Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome	July 15, 2010	Phase 2
NCT03573024	University of Colorado, Denver\|AbbVie	Acute Myeloid Leukemia	November 14, 2018	Phase 2
NCT04493138	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Recurrent Myeloproliferative Neoplasm	July 21, 2020	Phase 1\|Phase 2
NCT03217838	AstraZeneca	Acute Myeloid Leukaemia	July 31, 2017	Phase 1
NCT04173533	University of Birmingham	Acute Myeloid Leukemia\|Myelodysplasia	June 14, 2019	Phase 3
NCT01636609	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|High Risk Myelodysplastic Syndrome	November 20, 2012	Phase 1
NCT00006019	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lung Cancer\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Prostate Cancer	May 2000	Phase 2
NCT02721875	Boehringer Ingelheim	Myelodysplastic Syndromes	April 28, 2016	Phase 1
NCT00721214	Virginia Commonwealth University\|Celgene Corporation	Myelodysplastic Syndrome	July 2008	Phase 2
NCT03338348	University of Ulm\|Sunesis Pharmaceuticals	Acute Myeloid Leukemia\|Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)	April 19, 2018	Phase 2
NCT01926587	Onconova Therapeutics, Inc.	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia	August 2013	Phase 1\|Phase 2
NCT02472691	Heinrich-Heine University, Duesseldorf\|Celgene Corporation	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	May 2015	Phase 2
NCT02985190	Groupe Francophone des Myelodysplasies\|Celgene	MDS\|Systemic Autoimmune Diseases	January 26, 2017	Phase 2
NCT02966782	AbbVie\|Celgene; Genentech, Inc.	Myelodysplastic Syndromes (MDS)	March 7, 2017	Phase 1
NCT03092674	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts-2	December 22, 2017	Phase 2\|Phase 3
NCT05048615	Hospital Universitario Dr. Jose E. Gonzalez	AML	July 26, 2021	Phase 2
NCT03683433	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Chronic Myelomonocytic Leukemia\|IDH2 Gene Mutation\|Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	September 18, 2018	Phase 2
NCT00481273	Celgene	Myelodysplastic Syndromes	October 31, 2006
NCT01358734	Celgene	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia	April 27, 2012	Phase 2
NCT03226418	University of Nebraska\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	July 7, 2017	Phase 2
NCT01301820	French Innovative Leukemia Organisation\|Celgene Corporation	Acute Myeloid Leukemia	January 2011	Phase 2
NCT00895934	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	May 2009	Phase 1\|Phase 2
NCT01545947	Celgene	Carcinoma, Non-Small-Cell Lung\|Non-Small Cell Lung Cancer	May 1, 2012	Phase 1
NCT05317000	Barbara Burtness\|Yale University	Squamous Cell Carcinoma of Head and Neck	November 2022	Early Phase 1
NCT02281084	Celgene	Myelodysplastic Syndromes	July 6, 2015	Phase 2
NCT01873703	Helsinn Healthcare SA	Myelodysplastic Syndrome	June 2013	Phase 2
NCT00728520	Kansas City Veteran Affairs Medical Center	Acute Myeloid Leukemia\|Elderly	July 2008	Phase 2
NCT00313586	National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA\|Alkylating Agent-Related Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome\|Untreated Adult Acute Myeloid Leukemia	August 2006	Phase 2
NCT01129180	Pierluigi Porcu\|Millennium Pharmaceuticals, Inc.\|Celgene Corporation\|Ohio State University Comprehensive Cancer Center	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Hepatosplenic T-cell Lymphoma\|Peripheral T-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Prolymphocytic Leukemia\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Small Intestine Lymphoma\|T-cell Large Granular Lymphocyte Leukemia	May 2010	Phase 1
NCT05075460	Peking Union Medical College Hospital	T-cell Lymphoma	October 1, 2021	Phase 3
NCT05209152	Amgen	Higher Risk Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	November 7, 2022	Phase 1
NCT05379166	Uma Borate\|Ohio State University Comprehensive Cancer Center	Secondary Myelodysplastic Syndrome\|Therapy-Related Myelodysplastic Syndrome	June 30, 2022	Phase 2
NCT05361057	Institute of Hematology & Blood Diseases Hospital	Acute Myeloid Leukemia\|Measurable Disease	May 1, 2022	Phase 2
NCT01700673	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	June 2013	Phase 2
NCT04905810	Brian Jonas\|AbbVie\|National Cancer Institute (NCI)\|University of California, Davis	Acute Myeloid Leukemia\|Recurrent Acute Myeloid Leukemia	February 9, 2022	Phase 2
NCT04227847	Seagen Inc.	Myelodyspastic Syndrome\|Acute Myeloid Leukemia	August 7, 2020	Phase 1
NCT01720225	M.D. Anderson Cancer Center	Leukemia	November 6, 2012	Phase 2
NCT00336063	National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-Cell Lymphoma\|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma\|Recurrent Nasopharyngeal Undifferentiated Carcinoma\|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7\|Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7	March 3, 2006	Phase 1
NCT00005639	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma\|Small Intestine Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	March 2000	Phase 1
NCT01757535	Celgene	Leukemia, Myeloid, Acute	April 24, 2013	Phase 3
NCT00005598	University of Michigan Rogel Cancer Center\|National Cancer Institute (NCI)	Myelodysplastic Syndromes	October 2000	Phase 2
NCT04866056	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Myelodysplastic Syndromes\|Myeloproliferative Neoplasms\|Myelofibrosis	January 2022	Phase 1\|Phase 2
NCT04248595	Ge Zheng\|Zhongda Hospital	Acute Myeloid Leukemia	December 1, 2019	Phase 2
NCT00495547	PETHEMA Foundation\|Roche Pharma AG\|Celgene Corporation	Myelodysplastic Syndrome	February 2009	Phase 2
NCT05292664	Andrew E. Place\|AbbVie\|Servier\|Children´s Cancer Research Fund\|University of Colorado, Denver\|Boston Children´s Hospital\|Dana-Farber Cancer Institute	Myelodysplastic Syndromes, de Novo\|Myelodysplastic Syndromes, Secondary\|Myelodysplastic Syndromes, Previously Treated\|Treatment-Related Acute Myeloid Leukemia\|Therapy-Related Myelodysplastic Syndrome\|Acute Lymphoblastic Leukemia, in Relapse\|Acute Lymphoblastic Leukemia With Failed Remission\|Lymphoblastic Lymphoma, in Relapse\|Lymphoblastic Lymphoma, Refractory\|Acute Leukemia of Ambiguous Lineage in Relapse\|Acute Leukemia of Ambiguous Lineage Not Having Achieved Remission	October 2022	Phase 1
NCT00569010	M.D. Anderson Cancer Center\|Celgene Corporation	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome\|Leukemia	December 2005	Phase 1\|Phase 2
NCT01814826	Millennium Pharmaceuticals, Inc.\|Takeda	Acute Myelogenous Leukemia	April 10, 2013	Phase 1
NCT04401748	AbbVie\|Genentech, Inc.	Myelodysplastic Syndrome (MDS)	September 10, 2020	Phase 3
NCT01993641	Helsinn Healthcare SA	Myelodysplastic Syndrome\|MDS	December 2013	Phase 2
NCT04505995	Air Force Military Medical University, China\|Qilu Hospital of Shandong University\|Taian City Central Hospital\|The Affiliated Hospital of Qingdao University\|The Second Hospital of Hebei Medical University\|Children´s Hospital of Hebei Province	JMML	January 1, 2020	Not Applicable
NCT01260714	National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With Minimal Differentiation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Alkylating Agent-Related Acute Myeloid Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	December 2010	Phase 1
NCT00384839	US Oncology Research\|Celgene Corporation\|University of Southern California	Prostate Cancer	April 2006	Phase 2
NCT04146038	Rutgers, The State University of New Jersey\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	October 26, 2020	Phase 2
NCT02940483	The University of Texas Health Science Center, Houston	Brain Tumor Recurrent	February 1, 2017	Early Phase 1
NCT01015352	Groupe Francophone des Myelodysplasies\|Celgene Corporation\|Roche Pharma AG	Myelodysplastic Syndromes	February 2009	Phase 2
NCT03701295	National Cancer Institute (NCI)	Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Leukemia Cutis\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	January 16, 2019	Phase 1\|Phase 2
NCT05183035	LLS PedAL Initiative, LLC\|Princess Maxima Center for Pediatric Oncology (European Sponsor)\|AbbVie\|Roche-Genentech\|EuPAL	Acute Myeloid Leukemia	October 1, 2022	Phase 3
NCT03684811	Forma Therapeutics, Inc.	Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)\|Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)\|Cohort 3a and 3b: Chondrosarcoma\|Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma\|Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations	November 1, 2018	Phase 1\|Phase 2
NCT01599325	Celgene	Myelodysplastic Syndrome (MDS)	July 24, 2012	Phase 2
NCT01235117	University of Leeds\|National Cancer Institute (NCI)	Leukemia	January 2010	Phase 2
NCT00102687	Celgene	Myelodysplastic Syndromes	January 1, 2005	Phase 2
NCT01048034	Nordic MDS Group	Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	January 2010	Phase 2
NCT03628209	H. Lee Moffitt Cancer Center and Research Institute\|Bristol-Myers Squibb	Osteosarcoma\|Osteosarcoma in Children\|Osteosarcoma Recurrent\|Sarcoma	October 3, 2019	Phase 1\|Phase 2
NCT02719574	Forma Therapeutics, Inc.	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia\|Myelodysplastic Syndrome	April 2016	Phase 1\|Phase 2
NCT04912063	AbbVie	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	June 25, 2021	Phase 1
NCT03709576	Milton S. Hershey Medical Center\|Millennium Pharmaceuticals, Inc.\|Takeda	Acute Myeloid Leukemia (AML)	July 18, 2018	Phase 2
NCT02399917	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	April 20, 2015	Phase 2
NCT01652781	Seoul St. Mary´s Hospital\|Celgene Corporation	Myelodysplastic Syndrome	March 2012	Phase 2
NCT01386346	Weill Medical College of Cornell University\|Celgene Corporation	Esophageal Cancer\|Malignant Neoplasm of Cardio-esophageal Junction of Stomach	June 2011	Phase 1
NCT00652626	Celgene	MDS\|AML\|Solid Tumors\|Multiple Myeloma\|Non-Hodgkin´s Lymphoma\|Hodgkin´s Disease	November 1, 2008	Phase 1
NCT00118196	Medical University of South Carolina	Leukemia\|Myelodysplastic Syndromes	April 2005	Phase 2
NCT02201329	Boehringer Ingelheim	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	August 2014	Phase 1
NCT02750254	Washington University School of Medicine	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Acute Lymphocytic Leukemia	June 27, 2016	Phase 1
NCT04958486	The University of Texas Health Science Center, Houston	Fossa Ependymoma	July 8, 2021	Early Phase 1
NCT00326170	M.D. Anderson Cancer Center\|Celgene Corporation	Myelodysplastic Syndrome\|Acute Myelogenous Leukemia	July 2005	Phase 2
NCT01039155	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Hematopoietic and Lymphoid Cell Neoplasm	December 2009	Phase 1
NCT02942290	AbbVie\|Genentech, Inc.	Myelodysplastic Syndromes (MDS)	January 12, 2017	Phase 1
NCT05376111	The First Affiliated Hospital of Soochow University\|Jining Medical University\|The Second People´s Hospital of Huai´an\|First Affiliated Hospital Bengbu Medical College\|Northern Jiangsu Province People´s Hospital\|Affiliated Hospital of Nantong University\|Suzhou Hospital of Traditional Chinese Medicine	T-cell Acute Lymphoblastic Leukemia\|Recruiting	April 1, 2022	Phase 2
NCT01305135	Groupe Francophone des Myelodysplasies	High Grade Myelodysplastic Syndrome Lesions	December 30, 2010	Phase 1\|Phase 2
NCT04778410	Gilead Sciences	Myeloid Malignancies	June 28, 2021	Phase 2
NCT00443261	University of Kansas Medical Center\|Celgene Corporation	Squamous Cell Carcinoma	February 2007	Phase 1
NCT05179213	Peking Union Medical College Hospital\|Beijing Longfu Hospital	Angioimmunoblastic T-cell Lymphoma	January 1, 2022	Phase 2
NCT05168202	Bristol-Myers Squibb	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	January 19, 2022	Phase 1
NCT01155583	Case Comprehensive Cancer Center	Refractory Multiple Myeloma	June 2010	Phase 1\|Phase 2
NCT01462578	Technische Universität Dresden	Acute Myelocytic Leukemia\|Myelodysplastic Syndrome	September 2011	Phase 2
NCT01488565	Peter MacCallum Cancer Centre, Australia\|GlaxoSmithKline\|Celgene Corporation	Myelodysplastic Syndromes (MDS)\|Acute Myeloid Leukaemia (AML)	December 2010	Phase 2
NCT00352001	Mikkael Sekeres MD\|National Cancer Institute (NCI)\|Case Comprehensive Cancer Center	Leukemia\|Myelodysplastic Syndromes	May 2006	Phase 1\|Phase 2
NCT01193517	M.D. Anderson Cancer Center\|Celgene	Colorectal Cancer	August 2010	Phase 1\|Phase 2
NCT04266301	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	June 8, 2020	Phase 3
NCT03769532	Technische Universität Dresden\|Merck Sharp & Dohme LLC	Acute Myeloid Leukemia	August 21, 2019	Phase 2
NCT00748553	University of Utah\|Celgene Corporation	Advanced or Metastatic Solid Tumors\|Advanced or Metastatic Breast Cancer	September 2008	Phase 1\|Phase 2
NCT01053806	Tel-Aviv Sourasky Medical Center	Myelodysplastic Syndrome	August 2011	Phase 2
NCT04501120	Ascentage Pharma Group Inc.\|Suzhou Yasheng Pharmaceutical Co., Ltd.	Relapsed+Refractory Acute Myeloid Leukaemia\|Myeloid Malignancy	September 28, 2020	Phase 1\|Phase 2
NCT01747499	Washington University School of Medicine\|The Foundation for Barnes-Jewish Hospital\|National Cancer Institute (NCI)\|National Institutes of Health (NIH)	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	April 15, 2013	Phase 1\|Phase 2
NCT05144243	AbbVie\|Genentech, Inc.	Acute Myeloid Leukemia (AML)	January 6, 2022	Phase 4
NCT02018926	Mirati Therapeutics Inc.	Myelodysplastic Syndrome	December 2013	Phase 1\|Phase 2
NCT05197426	Bristol-Myers Squibb	Acute Myeloid Leukemia	January 17, 2022	Phase 2
NCT03588078	Groupe Francophone des Myelodysplasies\|Aprea Therapeutics	Myelodysplastic Syndrome With Gene Mutation\|Acute Myeloid Leukemia With Gene Mutations\|Myeloproliferative Neoplasm\|Chronic Myelomonocytic Leukemia	September 15, 2018	Phase 1\|Phase 2
NCT00398450	University of California, San Diego\|National Cancer Institute (NCI)	Melanoma (Skin)	February 2006	Phase 1
NCT05053425	LanZhou University	Acute Myeloid Leukemia	October 20, 2021	Not Applicable
NCT00413478	M.D. Anderson Cancer Center\|Celgene Corporation	Chronic Lymphocytic Leukemia\|Leukemia	September 2006	Phase 2
NCT03564873	University of Colorado, Denver	High Grade Myelodysplastic Syndromes	September 17, 2018	Phase 1\|Phase 2
NCT04980885	Akeso	Acute Myeloid Leukemia	August 13, 2021	Phase 1\|Phase 2
NCT04023526	Janssen Research & Development, LLC\|argenx	Leukemia, Myeloid, Acute	July 29, 2019	Phase 2
NCT02038777	Pfizer	Acute Myeloid Leukemia	March 25, 2014	Phase 1
NCT05476770	Therapeutic Advances in Childhood Leukemia Consortium	Hematologic Malignancy\|AML\|ALL\|BPDCN\|MDS\|Lymphoblastic Lymphoma\|Lymphoma, B-Cell\|Lymphoma, T-Cell\|Hodgkin Lymphoma\|Mixed Phenotype Acute Leukemia\|Acute Undifferentiated Leukemia	November 11, 2022	Phase 1
NCT00379912	Larry Cripe, MD\|Celgene Corporation\|Ortho Biotech Clinical Affairs, L.L.C.\|Walther Cancer Institute\|Hoosier Cancer Research Network	Myelodysplastic Syndromes	September 2006	Phase 2
NCT02497404	Weill Medical College of Cornell University	Leukemia, Erythroblastic, Acute\|Myelodysplastic Syndromes	February 13, 2015	Phase 2
NCT04102020	AbbVie\|Roche-Genentech	Acute Myeloid Leukemia (AML)	March 26, 2020	Phase 3
NCT04553692	IGM Biosciences, Inc.	Solid Tumor\|Colorectal Cancer\|Non Hodgkin Lymphoma\|Sarcoma\|Chondrosarcoma\|Small Lymphocytic Lymphoma\|Chronic Lymphocytic Leukemia\|Acute Myeloid Leukemia	September 23, 2020	Phase 1
NCT05325099	National Taiwan University Hospital	Acute Kidney Disease	June 30, 2022	Phase 1\|Phase 2
NCT01050790	Virginia Commonwealth University\|National Cancer Institute (NCI)\|Celgene Corporation	Multiple Myeloma	January 2010	Not Applicable
NCT05457361	Nanfang Hospital of Southern Medical University\|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Zhongshan People´s Hospital, Guangdong, China\|Shenzhen Hospital of Southern Medical University\|Peking University Shenzhen Hospital\|Shenzhen Second People´s Hospital\|The Seventh Affiliated Hospital of Sun Yat-sen University\|Southern Medical University, China\|First People´s Hospital of Chenzhou\|The Affiliated Hospital of Qingdao University\|First Affiliated Hospital of Guangxi Medical University	Venetoclax Combined With Azacitidine Plus Homoharringtonine\|Venetoclax Combined With Azacitidine	March 1, 2022	Phase 3
NCT04068597	CellCentric Ltd.	Haematological Malignancy\|Acute Myeloid Leukemia\|Non Hodgkin Lymphoma\|Multiple Myeloma\|Higher-risk Myelodysplastic Syndrome	August 9, 2019	Phase 1\|Phase 2
NCT05162976	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Classic Hodgkin Lymphoma\|Refractory Classic Hodgkin Lymphoma	January 3, 2022	Phase 1
NCT03513484	Northwestern University\|Robert H. Lurie Cancer Center\|Boehringer Ingelheim\|National Cancer Institute (NCI)	Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A\|Fibroblast Growth Factor Basic Form Measurement\|FLT3 Internal Tandem Duplication\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	November 14, 2018	Phase 1
NCT05428969	Faron Pharmaceuticals Ltd	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndromes\|Relapsed+Refractory AML	June 2, 2022	Phase 1\|Phase 2
NCT01718366	Groupe Francophone des Myelodysplasies\|Novartis	MDS	February 2013	Phase 1\|Phase 2
NCT03151408	Helsinn Healthcare SA\|Clinipace Worldwide	Acute Myeloid Leukemia	June 23, 2017	Phase 3
NCT04752163	M.D. Anderson Cancer Center	Hematopoietic and Lymphoid Cell Neoplasm\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	March 25, 2021	Phase 1\|Phase 2
NCT01110473	AbbVie (prior sponsor, Abbott)\|AbbVie	Acute Lymphoblastic Leukemia\|Acute Myelogenous Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Chronic Myelogenous Leukemia\|Myelodysplasia	April 2010	Phase 1
NCT00454480	The University of New South Wales\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	August 2006	Phase 2\|Phase 3
NCT04313881	Gilead Sciences	Myelodysplastic Syndromes	September 9, 2020	Phase 3
NCT03813147	National Cancer Institute (NCI)\|Children´s Oncology Group	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Myelodysplastic Syndrome	May 1, 2019	Phase 1
NCT02530463	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndrome\|Recurrent Myelodysplastic Syndrome	September 8, 2015	Phase 2
NCT05182957	The First Affiliated Hospital of Soochow University	Relapsed+Refractory Peripheral T-cell Lymphoma	December 14, 2021	Phase 2
NCT04257448	GWT-TUD GmbH\|Celgene\|AstraZeneca	Pancreas Cancer\|Pancreatic Adenocarcinoma\|Pancreatic Ductal Adenocarcinoma	May 25, 2020	Phase 1\|Phase 2
NCT05554419	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT03066648	Novartis Pharmaceuticals\|Novartis	Leukemia\|Leukemia, Myeloid\|Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Preleukemia\|Bone Marrow Diseases\|Hematologic Diseases\|Chronic Myelomonocytic Leukemia	July 6, 2017	Phase 1
NCT03390296	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	December 27, 2017	Phase 1\|Phase 2
NCT05469737	Bristol-Myers Squibb	Myelodysplastic Syndromes	November 30, 2022	Phase 2\|Phase 3
NCT03072043	H. Lee Moffitt Cancer Center and Research Institute\|Aprea Therapeutics	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Myeloproliferative Neoplasm\|Chronic Myelomonocytic Leukemia	May 18, 2017	Phase 1\|Phase 2
NCT00923234	Technische Universität Dresden\|Celgene Corporation	Myelodysplastic Syndromes\|Acute Myelogenous Leukemia	June 2009	Phase 1
NCT05155709	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	May 17, 2022	Phase 1\|Phase 2
NCT02323139	Groupe Francophone des Myelodysplasies\|Novartis	MDS	February 10, 2015	Phase 1
NCT02835794	University of Florida\|Teva Pharmaceutical Industries, Ltd.	Myelodysplastic Syndromes	August 2016	Phase 1\|Phase 2
NCT01442714	Stanford University\|Celgene Corporation	Leukemia\|Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndromes (MDS)	August 2011	Phase 2
NCT03284593	University Hospital, Toulouse	Acute Myeloid Leukemia	December 2014
NCT04230564	Pfizer	Leukemia, Myeloid, Acute	October 31, 2020
NCT03248479	Gilead Sciences	Hematological Malignancies	September 8, 2017	Phase 1
NCT04184505	Gruppo Italiano Malattie EMatologiche dell´Adulto	High-risk MDS	November 27, 2020	Phase 3
NCT00946647	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|Acute Myeloid Leukemia	December 2, 2009	Phase 1\|Phase 2
NCT04485052	Innovent Biologics (Suzhou) Co. Ltd.	Acute Myeloid Leukemia	September 25, 2020	Phase 1\|Phase 2
NCT04062266	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Genentech, Inc.	Acute Myeloid Leukemia in Remission\|FLT3 Gene Mutation\|Hematologic and Lymphocytic Disorder\|Acute Myeloid Leukemia\|Minimal Residual Disease Persistence\|Therapy-Related Acute Myeloid Leukemia	September 13, 2019	Phase 2
NCT03843528	Johns Hopkins All Children´s Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Mixed Phenotype Acute Leukemia\|Juvenile Myelomonocytic Leukemia	May 1, 2019	Phase 1
NCT03530683	Pfizer	Lymphoma\|Multiple Myeloma\|Acute Myeloid Leukemia\|Diffuse Large B-Cell Lymphoma	June 7, 2018	Phase 1
NCT05226455	Groupe Francophone des Myelodysplasies\|AbbVie	MDS\|AML	September 1, 2022	Phase 1\|Phase 2
NCT05442216	Joshua Zeidner\|Stemline Therapeutics, Inc.\|University of North Carolina, Chapel Hill\|Hoosier Cancer Research Network	Acute Myeloid Leukemia	December 2022	Phase 2
NCT01349959	National Cancer Institute (NCI)	Male Breast Carcinoma\|Recurrent Breast Carcinoma\|Stage IIIC Breast Cancer AJCC v7\|Stage IV Breast Cancer AJCC v6 and v7\|Triple-Negative Breast Carcinoma	April 21, 2011	Phase 2
NCT04336982	Celgene\|AbbVie	Leukemia, Myeloid, Acute	August 5, 2020	Phase 1\|Phase 2
NCT02447666	Celgene	Myelodysplastic Syndrome\|Leukemia, Myelomonocytic, Juvenile	September 15, 2015	Phase 2
NCT05305859	The First Affiliated Hospital of Xiamen University\|Fujian Provincial Hospital\|Fujian Cancer Hospital\|Zhangzhou manicipal hospital of Fujian Province\|Jieyang People´s Hospital\|Dongguan People´s Hospital\|Huizhou Municipal Central Hospital	Leukemia, Myeloid, Acute\|Relapsed Adult AML\|Refractory Leukemia	April 1, 2022	Phase 2
NCT03493646	Kirby Institute\|Celgene	Myelodysplastic Syndromes\|Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia	June 18, 2018	Phase 2
NCT02954653	Pfizer	Acute Myeloid Leukemia	November 28, 2016	Phase 1
NCT05079230	Gilead Sciences	Acute Myeloid Leukemia	July 7, 2022	Phase 3
NCT02828358	National Cancer Institute (NCI)	Acute Leukemia of Ambiguous Lineage\|B Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia	March 27, 2017	Phase 2
NCT02543879	Forma Therapeutics, Inc.	Acute Myeloid Leukemia\|Acute Myelogenous Leukemia\|Myelodysplastic Syndrome\|Non-Hodgkin Lymphoma	September 2015	Phase 1
NCT05048498	Nanexa AB\|Uppsala University	Myelodysplastic Syndromes (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|Acute Myeloid Leukemia (AML)	April 27, 2021	Phase 1
NCT01324960	Groupe Francophone des Myelodysplasies\|EpiCept Corporation	Myelodysplastic Syndromes	March 2011	Phase 1\|Phase 2
NCT04150029	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	September 1, 2020	Phase 2
NCT04518345	Uma Borate\|Sumitomo Pharma Oncology, Inc.\|Ohio State University Comprehensive Cancer Center	Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	November 5, 2020	Phase 1\|Phase 2
NCT05175508	The First Affiliated Hospital of Soochow University	AML\|MDS\|Old Age; Debility\|Hematologic Cancer	May 1, 2021	Phase 2\|Phase 3
NCT04086264	ImmunoGen, Inc.\|Jazz Pharmaceuticals	Acute Myeloid Leukemia	November 6, 2019	Phase 1\|Phase 2
NCT03259516	St. Petersburg State Pavlov Medical University	Myelodysplastic Syndromes	May 25, 2017	Phase 1\|Phase 2
NCT04809181	First Affiliated Hospital of Zhejiang University\|Second Affiliated Hospital, School of Medicine, Zhejiang University\|Zhejiang Provincial People´s Hospital\|The First Affiliated Hospital of Zhejiang Chinese Medical University\|Sir Run Run Shaw Hospital\|First Affiliated Hospital of Wenzhou Medical University\|Ningbo No. 1 Hospital\|Yinzhou Hospital Affiliated to Medical School of Ningbo University\|Jinhua Central Hospital\|Taizhou Hospital\|Union hospital of Fujian Medical University\|Xiangya Hospital of Central South University	Hematologic Malignancy\|Stem Cell Transplant Complications	March 19, 2021	Phase 2
NCT03264404	Rachael A Safyan, MD\|Columbia University	Pancreas Cancer	October 1, 2017	Phase 2
NCT02807558	Syros Pharmaceuticals	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	August 2016	Phase 2
NCT01571648	Celgene	Myelodysplastic Syndromes	April 1, 2012	Phase 1
NCT02951156	Pfizer\|EMD Serono	Diffuse Large B-Cell Lymphoma	December 16, 2016	Phase 3
NCT00439673	Gruppo Italiano Malattie EMatologiche dell´Adulto	Myelodysplastic Syndromes	May 2007	Phase 2
NCT05042531	LanZhou University\|Beijing Health Alliance Charitable Foundation	Acute Myeloid Leukemia	November 13, 2021	Not Applicable
NCT02158936	Novartis Pharmaceuticals\|Novartis	Thrombocytopaenia	June 10, 2014	Phase 3
NCT04687761	PETHEMA Foundation	Leukemia, Myeloid, Acute\|De Novo\|Age More 60yr	November 4, 2020	Phase 1\|Phase 2
NCT04284787	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	August 3, 2020	Phase 2
NCT03932318	Actinium Pharmaceuticals	Acute Myeloid Leukemia\|Relapsed Adult AML	March 2023	Phase 1\|Phase 2
NCT01254890	M.D. Anderson Cancer Center\|Bayer\|Onyx Therapeutics, Inc.\|Celgene	Leukemia	January 2011	Phase 1\|Phase 2
NCT04799275	National Cancer Institute (NCI)	Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|Grade 3b Follicular Lymphoma\|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Intravascular Large B-Cell Lymphoma\|Lymphoplasmacytic Lymphoma\|Nodular Lymphocyte Predominant Hodgkin Lymphoma\|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type\|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma\|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma	March 19, 2021	Phase 2\|Phase 3
NCT00118287	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Secondary Myelodysplastic Syndromes	April 2005	Phase 1\|Phase 2
NCT00890929	Stanford University\|Celgene Corporation	Acute Myeloid Leukemia (AML)\|Adult Acute Myeloblastic Leukemia	April 2009	Phase 1\|Phase 2
NCT02782468	Millennium Pharmaceuticals, Inc.\|Takeda	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	May 16, 2016	Phase 1
NCT05140811	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.\|Institute of Hematology & Blood Diseases Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	January 1, 2022	Phase 1\|Phase 2
NCT04484363	Takeda	Myelodysplastic Syndromes
NCT01886573	National Cancer Institute (NCI)	Stage IA Non-Small Cell Lung Carcinoma\|Stage IB Non-Small Cell Lung Carcinoma\|Stage IIA Non-Small Cell Lung Carcinoma\|Stage IIB Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer	June 2013	Phase 1
NCT04748848	Celgene	Leukemia, Myeloid	October 14, 2021	Phase 1
NCT03593018	The Lymphoma Academic Research Organisation\|Celgene	Relapsed Angioimmunoblastic T-Cell Lymphoma\|Refractory Angioimmunoblastic T-cell Lymphoma	November 9, 2018	Phase 3
NCT04755244	ALX Oncology Inc.	Acute Myeloid Leukemia\|AML, Adult	May 5, 2021	Phase 1\|Phase 2
NCT05401097	Alice Mims\|Ohio State University Comprehensive Cancer Center	Acute Myeloid Leukemia	August 1, 2022	Phase 2
NCT00842582	Loyola University\|Celgene Corporation	Ovarian Cancer	February 2009	Phase 1
NCT03173248	Institut de Recherches Internationales Servier\|Servier	Newly Diagnosed Acute Myeloid Leukemia (AML)\|Untreated AML\|AML Arising From Myelodysplastic Syndrome (MDS)\|Leukemia, Myeloid, Acute	June 26, 2017	Phase 3
NCT05141682	Jonathan Brammer\|Bristol-Myers Squibb\|Ohio State University Comprehensive Cancer Center	T-Cell Large Granular Lymphocyte Leukemia	May 1, 2022	Phase 1\|Phase 2
NCT02204020	University of Pittsburgh	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	April 2015	Phase 2
NCT05074355	University Health Network, Toronto	Myeloproliferative Neoplasm	May 16, 2022	Phase 2
NCT03572530	The University of Texas Health Science Center, Houston	Recurrent Ependymoma	February 8, 2019	Phase 1
NCT05586074	Sunshine Lake Pharma Co., Ltd.	Leukemia, Acute Myeloid (AML)	November 28, 2022	Phase 3
NCT01088373	Groupe Francophone des Myelodysplasies\|Celgene	Myelodysplastic Syndromes	March 25, 2010	Phase 2
NCT05566054	The First Affiliated Hospital of Soochow University\|Jining Medical University\|The Second People´s Hospital of Huai´an\|First Affiliated Hospital Bengbu Medical College\|Northern Jiangsu Province People´s Hospital\|Affiliated Hospital of Nantong University\|Suzhou Hospital of Traditional Chinese Medicine\|Taizhou University	Acute Monocytic Leukemia\|Newly Diagnosed	March 1, 2022	Phase 2
NCT04216355	Fujian Medical University	MDS-EB	January 2020	Phase 2\|Phase 3
NCT04629443	Institut de Recherches Internationales Servier\|ADIR, a Servier Group company\|Servier	Acute Myeloid Leukaemia	February 17, 2021	Phase 1\|Phase 2
NCT01207726	National Cancer Institute (NCI)	Stage IA Non-Small Cell Lung Carcinoma\|Stage IB Non-Small Cell Lung Carcinoma	September 2010	Phase 2
NCT04602273	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias\|Hospital Son Llatzer\|Germans Trias i Pujol Hospital\|Celgene Corporation	Myelodysplastic Syndromes	December 12, 2016
NCT00569660	M.D. Anderson Cancer Center\|Celgene Corporation	Myelofibrosis	June 2005	Phase 2
NCT03703375	Celgene	Lymphoma, T-Cell	November 6, 2018	Phase 3
NCT03047993	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia\|Blasts 20-30 Percent of Bone Marrow Nucleated Cells\|Blasts 20-30 Percent of Peripheral Blood White Cells\|Chronic Myelomonocytic Leukemia\|High Risk Myelodysplastic Syndrome\|IPSS Risk Category Intermediate-2\|Myelodysplastic Syndrome	November 15, 2017	Phase 1\|Phase 2
NCT04078399	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	HSCT\|Efficacy and Safety	August 28, 2019	Not Applicable
NCT03941496	Andrew Dinardo\|Bristol-Myers Squibb\|Baylor College of Medicine	Tuberculosis, Pulmonary	September 2022	Phase 1\|Phase 2
NCT00004062	Lucille P. Markey Cancer Center at University of Kentucky\|National Cancer Institute (NCI)	Head and Neck Cancer	July 1999	Phase 1
NCT02677922	Celgene	Leukemia, Myeloid, Acute	June 3, 2016	Phase 1\|Phase 2
NCT02367456	Pfizer	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia	April 28, 2015	Phase 1
NCT01379274	Rush University Medical Center\|Celgene Corporation	MDS	January 2011	Phase 2
NCT04842604	Pfizer	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	May 17, 2021	Phase 3
NCT04878432	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndrome (MDS)	March 17, 2022	Phase 2
NCT04771130	BeiGene	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasm	May 24, 2021	Phase 1\|Phase 2
NCT05554393	National Cancer Institute (NCI)	Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT00412919	Bayside Health	Multiple Myeloma	December 2006	Phase 2
NCT01892371	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	FLT3 Gene Mutation Negative\|FLT3 Internal Tandem Duplication Positive\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	November 12, 2013	Phase 1\|Phase 2
NCT02993523	AbbVie\|Genentech, Inc.	Acute Myeloid Leukemia (AML)	February 2, 2017	Phase 3
NCT02750995	Daniel El Fassi\|Technical University of Denmark\|Herlev Hospital	Myelodysplastic Syndrome\|Acute Myeloid Leukemia	April 2016	Phase 1
NCT04623216	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	September 14, 2021	Phase 1\|Phase 2
NCT03613532	Jacqueline Garcia, MD\|National Institutes of Health (NIH)\|Dana-Farber Cancer Institute	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)\|Chronic Myelomonocytic Leukemia (CMML)\|MDS+Myeloproliferative Neoplasm-unclassifiable (MDS+MPN-unclassifiable)\|Hematopoietic Stem Cell Transplant	October 24, 2018	Phase 1
NCT04812548	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndrome (MDS)	May 31, 2021	Phase 2
NCT05262465	guomei\|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences	Adult Acute Myeloid Leukemia	July 1, 2020	Not Applicable
NCT04022785	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm\|Myeloproliferative Neoplasm	September 9, 2019	Phase 1
NCT04090736	PETHEMA Foundation\|Millennium Pharmaceuticals, Inc.\|Dynamic Science S.L.	Leukemia, Myeloid, Acute	September 24, 2019	Phase 3
NCT02829840	M.D. Anderson Cancer Center\|Ariad Pharmaceuticals	Leukemia\|FLT3-Mutated Acute Myeloid Leukemia\|FLT3-Mutated High-Risk Myelodysplastic Syndrome	September 2016	Phase 1\|Phase 2
NCT02953561	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	February 20, 2017	Phase 1\|Phase 2
NCT00934440	University of Kansas Medical Center\|Celgene	Renal Cell Carcinoma	June 2009	Phase 1\|Phase 2
NCT03593915	Sumitomo Pharma Oncology, Inc.	Myelodysplastic Syndromes (MDS)	August 29, 2018	Phase 1\|Phase 2
NCT04900350	Akeso	Myelodysplastic Syndrome	June 18, 2021	Phase 1\|Phase 2
NCT02343536	Celgene	Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Follicular	April 29, 2015	Phase 1
NCT03013998	Beat AML, LLC	Previously Untreated Acute Myeloid Leukemia	November 2016	Phase 1\|Phase 2
NCT00915252	University Hospital Muenster\|Celgene Corporation\|Amgen	Acute Myeloid Leukemia	July 2009	Phase 2
NCT01566695	Celgene	Myelodysplastic Syndrome	April 26, 2013	Phase 3
NCT03146871	University of Southern California\|National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Recurrent Adult Acute Myeloid Leukemia	April 20, 2017	Phase 2
NCT03094637	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	High Risk Myelodysplastic Syndrome\|IPSS Risk Category Intermediate-1\|Myelodysplastic Syndrome	November 6, 2017	Phase 2
NCT04256317	Astex Pharmaceuticals, Inc.	Myelodysplastic Syndromes\|Chronic Myelocytic Leukemia\|Acute Myeloid Leukemia\|Myelodysplastic Syndrome+Neoplasm	May 21, 2020	Phase 2\|Phase 3
NCT02508870	Hoffmann-La Roche	Myelodysplastic Syndromes	September 30, 2015	Phase 1
NCT03586609	M.D. Anderson Cancer Center	Acute Myeloid Leukemia	October 25, 2018	Phase 2
NCT02577406	Celgene	Leukemia, Myeloid\|Isocitrate Dehydrogenase	December 30, 2015	Phase 3
NCT01186939	Celgene	Myelodysplastic Syndromes	April 1, 2007	Phase 3
NCT05201066	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	January 2, 2023	Phase 2
NCT05270200	Zhujiang Hospital	Leukemia, Myeloid, Acute	February 1, 2022	Phase 1\|Phase 2
NCT04797780	Syros Pharmaceuticals	Myelodysplastic Syndromes	February 8, 2021	Phase 3
NCT04417517	ALX Oncology Inc.	Higher Risk Myelodysplastic Syndromes	October 2, 2020	Phase 1\|Phase 2
NCT03450343	Medical University of South Carolina\|Celgene Corporation	Large B-Cell Diffuse Lymphoma	April 4, 2019	Phase 1
NCT01338337	Asociación Andaluza de Hematología y Hemoterapia	Myelodysplastic Syndrome (MDS)	November 2010	Phase 2
NCT04550442	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Genentech, Inc.	Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome\|Therapy-Related Myelodysplastic Syndrome	September 4, 2020	Phase 1\|Phase 2
NCT04128020	Sherif Farag\|Big Ten Cancer Research Consortium	Aml\|AML, Adult	October 10, 2019	Phase 1
NCT02785900	Seagen Inc.	Acute Myeloid Leukemia	May 2016	Phase 3
NCT02706899	Seagen Inc.	Myelodysplastic Syndrome	February 2016	Phase 1\|Phase 2
NCT00629343	Columbia University\|Schering-Plough\|Celgene Corporation	Soft Tissue Sarcoma\|Mesothelioma	October 2007	Phase 1
NCT02995655	Washington University School of Medicine\|Cantex Pharmaceuticals	Myelodysplastic Syndromes\|Acute Myeloid Leukemia\|AML\|MDS	April 7, 2017	Phase 1
NCT05554406	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic+Myeloproliferative Neoplasm\|Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Therapy-Related Acute Myeloid Leukemia	February 28, 2023	Phase 2
NCT03471260	M.D. Anderson Cancer Center	Acute Myeloid Leukemia\|Hematopoietic and Lymphoid System Neoplasm\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	March 19, 2018	Phase 1\|Phase 2
NCT02775903	Celgene	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	June 3, 2016	Phase 2
NCT04407442	University of California, San Francisco\|Janssen Pharmaceuticals\|Multiple Myeloma Research Foundation	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	November 30, 2020	Phase 2
NCT01342692	Assistance Publique - Hôpitaux de Paris	MDS	June 2011	Phase 2
NCT03814005	Takeda	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute\|Renal Insufficiency\|Liver Disease\|Neoplasms	July 10, 2019	Phase 1
NCT03895671	Versailles Hospital	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	June 19, 2019	Phase 2
NCT04139434	Newave Pharmaceutical Inc	AML+MDS\|CMML\|Relapse\|Refractory Acute Lymphoblastic Leukemia\|Relapse Leukemia\|Relapsed Adult AML	July 6, 2020	Phase 1
NCT05520567	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia (AML)\|FLT3-mutated Acute Myeloid Leukemia	November 2, 2022	Phase 1\|Phase 2
NCT01912274	Helsinn Healthcare SA	Acute Myeloid Leukemia	December 24, 2013	Phase 2
NCT01292083	University of Southern California\|National Cancer Institute (NCI)	Recurrent Breast Cancer\|Stage IA Breast Cancer\|Stage IB Breast Cancer\|Stage II Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer\|Triple-negative Breast Cancer	January 2011	Not Applicable
NCT04490707	Ge Zheng\|Zhongda Hospital	Acute Myeloid Leukemia in Remission	September 1, 2020	Phase 3
NCT01067274	Acute Leukemia French Association\|Assistance Publique - Hôpitaux de Paris	Acute Myeloid Leukemia	April 2010	Phase 3
NCT02341495	Elizabeth Henry\|Loyola University	Acute Myeloid Leukemia	February 2013	Phase 2
NCT02303782	Oncoethix GmbH	Acute Myeloid Leukemia	January 2015	Phase 1\|Phase 2
NCT00911066	Millennium Pharmaceuticals, Inc.	Acute Myelogenous Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome	June 2009	Phase 1
NCT04372433	Immune-Onc Therapeutics\|California Institute for Regenerative Medicine (CIRM)	AML M5\|AML M4\|AML, Nos\|Acute Myelogenous Leukemia in Relapse\|Myelomonocytic Leukemia, Chronic	September 14, 2020	Phase 1
NCT03465540	Amgen	Multiple Myeloma\|Acute Myeloid Leukemia\|Non-Hodgkins Lymphoma\|Myelodysplastic Syndrome\|AML\|MDS\|NHL	August 17, 2018	Phase 1
NCT01083706	Fred Hutchinson Cancer Center\|Celgene Corporation\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Childhood Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	April 2010	Phase 2
NCT00658814	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Secondary Acute Myeloid Leukemia	December 1, 2008	Phase 2
NCT01241786	Hackensack Meridian Health\|Celgene Corporation	Chronic Lymphocytic Leukemia(CLL)\|Small Lymphocytic Lymphoma	July 2010	Phase 2
NCT05433532	The First Affiliated Hospital of Soochow University	Philadelphia Chromosome\|Acute Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Chronic Myeloid Leukemia\|Mixed Phenotype Acute Leukemia	May 1, 2022	Phase 2
NCT03719989	Seoul National University Hospital	Diffuse Large B Cell Lymphoma\|Relapsed Non Hodgkin Lymphoma\|Refractory Non-Hodgkin Lymphoma	December 1, 2018	Phase 2
NCT00761722	Celgene	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Lymphoma\|Multiple Myeloma\|Leukemia, Myelomonocytic, Chronic	August 12, 2008	Phase 1
NCT04734990	M.D. Anderson Cancer Center	Chronic Myelomonocytic Leukemia-0\|Chronic Myelomonocytic Leukemia-1\|Chronic Myelomonocytic Leukemia-2\|Myelodysplastic Syndrome\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome	July 7, 2021	Phase 1\|Phase 2
NCT05211570	AB Science	Acute Myeloid Leukemia Refractory\|Acute Myeloid Leukemia, in Relapse\|Myelodysplastic Syndrome Acute Myeloid Leukemia	June 1, 2022	Phase 1\|Phase 2
NCT04730258	Treadwell Therapeutics, Inc	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|AML\|MDS\|CMML	April 16, 2021	Phase 1\|Phase 2
NCT04487106	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	July 21, 2020	Phase 2
NCT01404741	Universitätsklinikum Hamburg-Eppendorf	Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia	July 2011	Phase 2
NCT03825367	Therapeutic Advances in Childhood Leukemia Consortium\|Bristol-Myers Squibb	AML, Childhood	November 29, 2019	Phase 1\|Phase 2
NCT02553941	Brian Jonas\|Pharmacyclics LLC.\|University of California, Davis	Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Refractory Anemia With Excess Blasts in Transformation\|Secondary Myelodysplastic Syndrome	May 17, 2016	Phase 1
NCT01152346	Bioniche Pharma USA LLC	Myelodysplastic Syndrome	April 2011	Phase 1
NCT04061239	GWT-TUD GmbH	MDS\|AML	August 19, 2019	Phase 2
NCT02959437	Incyte Corporation	Solid Tumors\|Advanced Malignancies\|Metastatic Cancer	February 27, 2017	Phase 1\|Phase 2
NCT01305460	Groupe Francophone des Myelodysplasies	Myelodysplastic Syndrome	July 5, 2011	Phase 1\|Phase 2
NCT02147873	TetraLogic Pharmaceuticals	Myelodysplastic Syndrome (MDS)\|Chronic Myelomonocytic Leukemia (CMML)	June 2014	Phase 2
NCT05564390	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	February 28, 2023	Phase 2
NCT01281124	National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Non-Small Cell Cancer AJCC v7	January 12, 2011	Phase 2
NCT00387465	National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	August 2006	Phase 1\|Phase 2
NCT02421939	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Leukemia, Acute Myeloid (AML)	October 20, 2015	Phase 3
NCT02942758	University Hospital Regensburg\|Anticancer Fund, Belgium\|Celgene	Acute Myeloid Leukemia	April 10, 2017	Phase 2
NCT04278768	Curis, Inc.	Acute Myelogenous Leukemia\|Myelodysplastic Syndrome	July 6, 2020	Phase 1\|Phase 2
NCT03850418	Henry Ford Health System	Myeloid Malignancy	July 1, 2019	Phase 2
NCT05381038	National University Hospital, Singapore\|The N.1 Institute for Health (N.1)\|Cancer Science Institute of Singapore	Solid Tumor\|Gastrointestinal Cancer\|Breast Cancer	June 2022	Phase 1\|Phase 2
NCT03326310	University of Chicago	Chronic Myeloid Leukemia\|Myelofibroses	September 4, 2018	Phase 1
NCT01928576	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Rising Tide Foundation\|Stand Up To Cancer\|Bristol-Myers Squibb\|Celgene\|Syndax Pharmaceuticals, Inc.\|Rhone-Poulenc Rorer	Non-Small Cell Lung Cancer\|Epigenetic Therapy	August 2013	Phase 2
NCT03926624	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	November 22, 2019	Phase 3
NCT02811497	University Health Network, Toronto	Microsatellite Stable Colorectal Carcinoma\|Platinum Resistant Epithelial Ovarian Cancer Type II\|Estrogen Receptor Positive and HER2 Negative Breast Cancer	September 2016	Phase 2
NCT00997243	Alison Walker\|Seagen Inc.\|Ohio State University Comprehensive Cancer Center	Leukemia\|Myelodysplastic Syndromes	November 2009	Phase 2
NCT05609942	Blueprint Medicines Corporation	Advanced Systemic Mastocytosis	December 1, 2022	Phase 1\|Phase 2
NCT01519011	Celgene	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic\|Leukemia, Myeloid, Acute	February 7, 2012	Phase 1
NCT03666559	Assistance Publique - Hôpitaux de Paris	Recurrent IDH1+2 Mutated Glioma	September 22, 2020	Phase 2
NCT01541280	Nantes University Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	November 2011	Phase 2
NCT01845805	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Pancreatic Cancer	January 10, 2014	Phase 2
NCT01093573	Brenda Cooper, MD\|National Cancer Institute (NCI)\|Case Comprehensive Cancer Center	Untreated Adult Acute Myeloid Leukemia	July 2009	Phase 1\|Phase 2
NCT01869114	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|de Novo Myelodysplastic Syndromes\|Myelodysplastic Syndrome With Isolated Del(5q)\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Myeloid Leukemia	July 8, 2013	Phase 2
NCT03416179	Pfizer	Leukemia, Myeloid, Acute	April 20, 2018	Phase 3
NCT05453903	Janssen Research & Development, LLC	Leukemia, Myeloid, Acute	October 4, 2022	Phase 1
NCT00005934	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health Clinical Center (CC)	Beta Thalassemia	June 2000	Phase 2
NCT00392353	National Cancer Institute (NCI)	Acute Erythroid Leukemia\|Acute Megakaryoblastic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Ring Sideroblasts\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia	November 22, 2006	Phase 1\|Phase 2
NCT05404906	The First Affiliated Hospital of Soochow University	Acute Myeloid Leukemia (AML) in Remission	June 25, 2022	Phase 2\|Phase 3
NCT02701673	M.D. Anderson Cancer Center	Lymphoma	June 2016	Phase 1\|Phase 2
NCT01201811	Celgene	Myelodysplastic Syndromes	October 1, 2010	Phase 4
NCT04214860	Aprea Therapeutics	Myeloid Malignancy	December 13, 2019	Phase 1
NCT00813124	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Celgene Corporation	Stem Cell Transplantation\|Leukemia	December 2008	Phase 2
NCT02711137	Incyte Corporation	Solid Tumors	May 18, 2016	Phase 1\|Phase 2
NCT01839240	University of Chicago\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	June 6, 2012	Phase 1
NCT00741234	S*BIO	Solid Tumors\|Hematologic Malignancies\|Myelodysplastic Syndrome	April 2007	Phase 1
NCT04187703	Benjamin Tomlinson\|Case Comprehensive Cancer Center	Myelodysplastic Syndromes\|MDS+MPN Crossover Syndromes	November 16, 2020	Early Phase 1
NCT04485065	Innovent Biologics (Suzhou) Co. Ltd.	Myelodysplastic Syndromes	September 30, 2020	Phase 1
NCT04638309	Aprea Therapeutics	MDS\|Myelodysplastic Syndromes	September 20, 2021	Phase 1
NCT04801797	Massachusetts General Hospital\|AbbVie	Acute Myeloid Leukemia	May 20, 2021	Phase 2
NCT01460498	M.D. Anderson Cancer Center\|Celgene Corporation	Leukemia	August 8, 2012	Phase 1
NCT01249430	National Cancer Institute (NCI)	Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	January 20, 2011	Phase 1
NCT03298516	Genentech, Inc.	Leukemia, Myeloid, Acute	November 15, 2017	Phase 1
NCT01390311	Washington University School of Medicine\|National Cancer Institute (NCI)	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes	April 2012	Phase 1
NCT00004871	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases	May 2000	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H ₂ O : 33.33 mg/mL ( 136.49 mM ; Need ultrasonic)

DMSO : ≥ 31 mg/mL ( 126.95 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0950 mL	20.4750 mL	40.9500 mL
5 mM	0.8190 mL	4.0950 mL	8.1900 mL
10 mM	0.4095 mL	2.0475 mL	4.0950 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 20 mg/mL (81.90 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12;21(35):5483-95.
[2] Creusot F, et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidineand 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041-8.
[3] Li LH,et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9.
[4] Marycz K, et al. 5-Azacytidine and Resveratrol Enhance Chondrogenic Differentiation of Metabolic Syndrome-Derived Mesenchymal Stem Cells by Modulating Autophagy.Oxid Med Cell Longev. 2019 May 12;2019:1523140.

Synonyms

1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl-

s-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl-

4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one

Antibiotic U 18496

5-Azacytidine

U 18496

NSC 102816

Azacitidine

Azacytidine

NSC 103-627

5-AZCR

Mylosar

5-AC

WR 183027

5-AzaC

5-AZC

Ladakamycin

Ledakamycin

Vidaza

CC 486

5-Azacitidine

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart